KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLoans and Notes ReceivablesLong-Term Debt IssuancesNon-Current ReceivablesReceivables Refunds
Ratios

Royalty Pharma (RPRX) Long-Term Debt Issuances (2020 - 2025)

Royalty Pharma (RPRX) has disclosed Long-Term Debt Issuances for 5 consecutive years, with $2.0 billion as the latest value for Q3 2025.

  • Quarterly Long-Term Debt Issuances changed N/A to $2.0 billion in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $483.2 million through Dec 2025, up 143.1% year-over-year, with the annual reading at $2.0 billion for FY2025, N/A changed from the prior year.
  • Long-Term Debt Issuances hit $2.0 billion in Q3 2025 for Royalty Pharma, up from -$1.5 billion in the prior quarter.
  • In the past five years, Long-Term Debt Issuances ranged from a high of $2.0 billion in Q3 2025 to a low of -$1.5 billion in Q4 2024.
  • Historically, Long-Term Debt Issuances has averaged $526.4 million across 4 years, with a median of $811.3 million in 2021.
  • Biggest five-year swings in Long-Term Debt Issuances: tumbled 78.25% in 2021 and later crashed 520.35% in 2024.
  • Year by year, Long-Term Debt Issuances stood at $1.3 billion in 2021, then tumbled by 72.5% to $350.0 million in 2023, then plummeted by 520.35% to -$1.5 billion in 2024, then soared by 232.85% to $2.0 billion in 2025.
  • Business Quant data shows Long-Term Debt Issuances for RPRX at $2.0 billion in Q3 2025, -$1.5 billion in Q4 2024, and $350.0 million in Q4 2023.